Adalimumab in the management of palmoplantar psoriasis

Journal of Drugs in Dermatology

Volumn 8, Issue 12, 2009, Pages 1136-1139

  Ghate, Jayashri V ^a   Alspaugh, Carrie D ^a  

^a Blue Ridge Dermatology Associates PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CEFALEXIN; TRIAMCINOLONE; ULOBETASOL PROPIONATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL CONSUMPTION; ALOPECIA; ARTHRALGIA; ARTICLE; BODY SURFACE; CASE REPORT; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; HAND JOINT; HUMAN; LIVER FUNCTION TEST; MALE; NAIL DYSTROPHY; NEUTROPHILIA; PUSTULOSIS PALMOPLANTARIS; SKIN BIOPSY; TOPICAL TREATMENT; DRUG ANTAGONISM; PSORIASIS;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74049101088     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Adişen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23(7):814-819.
2. Carr D, Tusa MG, Carroll CL, et al. Open-label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat. 2008;19(2):97-100. (Pubitemid 351891548)
3. Marsland AM, Griffiths CE. Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett. 2001;6(12):3-5.
4. Bonish B, Gordon KB. Palmoplantar psoriasis. In: Koo JYM, Lebwohl MG, Lee CS, eds. Mild-to-Moderate Psoriasis. 1st ed. New York, NY: Informa Healthcare; 2006:183-194.
5. Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2007;32(1):18-22. (Pubitemid 46006359)
6. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the comparative study of adalimumab (HUMIRA) versus methotrexate versus placebo in psoriasis patients (CHAMPION). Br J Dermatol. 2008;15(3):558-566. (Pubitemid 351239154)
7. Menter A, Tyring SK, Gordon KB, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
8. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets. 2006;10(6):817-831. (Pubitemid 44816746)
9. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week clinical trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549-557. (Pubitemid 351239150)
10. Revicki DR, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-350. (Pubitemid 350223202)
11. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57(6):963-971. (Pubitemid 350087343)
12. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24-28. (Pubitemid 43247304)
13. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003;72(5):396-398. (Pubitemid 37550146)
14. Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol. 2005;53(2 Suppl 1):S127-S129. (Pubitemid 40961826)
15. Spuls PI, Hadi S, Rivera L, Lebwohl M. Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat. 2003;14 Suppl 2:21-25. (Pubitemid 37474603)
16. Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg. 2007;11(6):202-205.
17. Colsman A, Carrascosa JM, Ferrandiz C, Simon JC. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. J Eur Acad Dermatol Venereol. 2008;22(9):1131-1134.
18. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56(1):e55-e79. (Pubitemid 44969298)
19. Leon A, Nguyen A, Letsinger J, Koo J. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: A review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother. 2007;8(5):617-632. (Pubitemid 46547015)
20. Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58(1):125-135. (Pubitemid 350298147)